Header Logo

Connection

Mark Pollack to Phobic Disorders

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Phobic Disorders.
Mark Pollack
Connection Strength
5.527
Phobic Disorders
  1. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014 Jan; 171(1):44-53.
    View in: PubMed
    Score: 0.414
  2. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
    View in: PubMed
    Score: 0.404
  3. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol. 2013 Dec; 81(6):1100-12.
    View in: PubMed
    Score: 0.403
  4. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul; 170(7):751-8.
    View in: PubMed
    Score: 0.400
  5. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
    View in: PubMed
    Score: 0.217
  6. Relationship between adult social phobia and childhood anxiety. Braz J Psychiatry. 2003 Jun; 25(2):96-9.
    View in: PubMed
    Score: 0.199
  7. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis. 2002 Jul; 190(7):453-6.
    View in: PubMed
    Score: 0.186
  8. Quality of life in social anxiety disorder compared with panic disorder and the general population. Psychiatr Serv. 2002 Jun; 53(6):714-8.
    View in: PubMed
    Score: 0.185
  9. New advances in the management of anxiety disorders. Psychopharmacol Bull. 2002; 36(4):79-94.
    View in: PubMed
    Score: 0.180
  10. Citalopram for social phobia: a clinical case series. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct; 25(7):1469-74.
    View in: PubMed
    Score: 0.177
  11. Prevalence of childhood ADHD among patients with Generalized Anxiety Disorder and a comparison condition, Social Phobia. Depress Anxiety. 2001; 13(4):190-1.
    View in: PubMed
    Score: 0.168
  12. Comorbidity, neurobiology, and pharmacotherapy of social anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 12:24-9.
    View in: PubMed
    Score: 0.168
  13. Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry. 1999; 60 Suppl 9:20-6.
    View in: PubMed
    Score: 0.146
  14. Social phobia: an update. Harv Rev Psychiatry. 1998 Jan-Feb; 5(5):247-59.
    View in: PubMed
    Score: 0.137
  15. Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
    View in: PubMed
    Score: 0.137
  16. The pharmacotherapy of social phobia. Int Clin Psychopharmacol. 1996 Jun; 11 Suppl 3:71-5.
    View in: PubMed
    Score: 0.122
  17. Smiles may go unseen in generalized social anxiety disorder: evidence from binocular rivalry for reduced visual consciousness of positive facial expressions. J Anxiety Disord. 2013 Oct; 27(7):619-26.
    View in: PubMed
    Score: 0.101
  18. Development of a brief version of the Social Phobia Inventory using item response theory: the Mini-SPIN-R. Behav Ther. 2013 Dec; 44(4):651-61.
    View in: PubMed
    Score: 0.099
  19. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry. 2013 Jun 01; 73(11):1054-8.
    View in: PubMed
    Score: 0.097
  20. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013 Feb; 47(2):168-74.
    View in: PubMed
    Score: 0.095
  21. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Depress Anxiety. 2012 Nov; 29(11):924-30.
    View in: PubMed
    Score: 0.094
  22. Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add? J Anxiety Disord. 2012 Aug; 26(6):665-72.
    View in: PubMed
    Score: 0.093
  23. Mood regulation and quality of life in social anxiety disorder: an examination of generalized expectancies for negative mood regulation. J Anxiety Disord. 2012 Apr; 26(3):435-41.
    View in: PubMed
    Score: 0.090
  24. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
    View in: PubMed
    Score: 0.078
  25. Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. Depress Anxiety. 2009; 26(11):1027-32.
    View in: PubMed
    Score: 0.073
  26. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Depress Anxiety. 2008; 25(6):496-505.
    View in: PubMed
    Score: 0.068
  27. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther. 2008; 14(3):165-70.
    View in: PubMed
    Score: 0.068
  28. Clonazepam in the treatment of panic disorder and agoraphobia. Psychopharmacol Bull. 1987; 23(1):141-4.
    View in: PubMed
    Score: 0.064
  29. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol. 1986 Oct; 6(5):302-4.
    View in: PubMed
    Score: 0.063
  30. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006 Mar; 63(3):298-304.
    View in: PubMed
    Score: 0.060
  31. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
    View in: PubMed
    Score: 0.060
  32. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
    View in: PubMed
    Score: 0.054
  33. WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
    View in: PubMed
    Score: 0.050
  34. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol. 2003 May; 18(3):169-72.
    View in: PubMed
    Score: 0.049
  35. Hypothyroidism and hyperthyroidism in anxiety disorders revisited: new data and literature review. J Affect Disord. 2002 May; 69(1-3):209-17.
    View in: PubMed
    Score: 0.046
  36. The anxiety sensitivity index: item analysis and suggestions for refinement. J Pers Assess. 2001 Oct; 77(2):272-94.
    View in: PubMed
    Score: 0.044
  37. Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress Anxiety. 2001; 14(4):209-13.
    View in: PubMed
    Score: 0.042
  38. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord. 2000 Jul-Aug; 14(4):345-58.
    View in: PubMed
    Score: 0.041
  39. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
    View in: PubMed
    Score: 0.037
  40. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998 Jul; 155(7):992-3.
    View in: PubMed
    Score: 0.035
  41. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord. 1997 Sep-Oct; 11(5):499-502.
    View in: PubMed
    Score: 0.033
  42. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
    View in: PubMed
    Score: 0.033
  43. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
    View in: PubMed
    Score: 0.026
  44. Cortico-limbic responses to masked affective faces across ptsd, panic disorder, and specific phobia. Depress Anxiety. 2014 Feb; 31(2):150-9.
    View in: PubMed
    Score: 0.025
  45. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan; 70(1):87-97.
    View in: PubMed
    Score: 0.024
  46. Major depression in panic disorder patients with comorbid social phobia. J Affect Disord. 1991 Jul; 22(3):171-7.
    View in: PubMed
    Score: 0.022
  47. Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry. 1990 Dec; 51 Suppl A:12-6.
    View in: PubMed
    Score: 0.021
  48. Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990 Nov; 51(11):470-2.
    View in: PubMed
    Score: 0.021
  49. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res. 1989 Jun; 28(3):345-50.
    View in: PubMed
    Score: 0.019
  50. Understanding the link between anxiety symptoms and suicidal ideation and behaviors in outpatients with bipolar disorder. J Affect Disord. 2007 Jan; 97(1-3):91-9.
    View in: PubMed
    Score: 0.015
  51. Effects of parental anxiety disorders in children at high risk for panic disorder: a controlled study. J Affect Disord. 2006 Aug; 94(1-3):191-7.
    View in: PubMed
    Score: 0.015
  52. Complicated grief and its correlates in patients with bipolar disorder. J Clin Psychiatry. 2005 Sep; 66(9):1105-10.
    View in: PubMed
    Score: 0.015
  53. Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996 Jun 20; 39(1):31-8.
    View in: PubMed
    Score: 0.008
  54. Childhood history of anxiety in adults with panic disorder: association with anxiety sensitivity and comorbidity. Harv Rev Psychiatry. 1994 Jan-Feb; 1(5):288-93.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.